Caspase-4在霍奇金及间变性大细胞淋巴瘤中的表达

目的:在利用基因芯片技术研究霍奇金氏淋巴瘤(HL)及间变性大细胞淋巴瘤(ALCL)细胞株凋亡相关基因的表达时发现caspase-4 在两者的mRNA表达水平存在明显差异的基础上,我们拟检测caspase-4在HL 及ALCL肿瘤组织中蛋白质水平的表达及试图探讨它们的表达与此两种淋巴瘤的发生机制的关系。方法:选取临床手术切除、石蜡包埋的标本HL 18例、ALCL 15例,4 μm厚连续切片,HE染色及CD30(Ber-H2)、CD15(C3D-1)、CD20(L26)、CD45RO(UCHL1) 等免疫组织化学染色,通过形态学和免疫分型进行严格的病例筛选,确定诊断。切片经微波抗原修复,抗caspase-4抗体(SP法)染片,DAB显色,光学显微镜高倍镜下计数阳性细胞。结果:在ALCL组,15/15例(100%)均高表达caspase-4;而在HL病例组16例(88.8%)不表达、2例(11.2%)弱表达caspase-4,两者表达差异显著(P<0.01)。结论:①Caspase-4在两种淋巴瘤中的表达存在明显差异,即在ALCL的表达明显高于在HL的表达。Caspase-4在HL和ALCL中表达的显著差异,提示两种肿瘤在发生发展的过程中存在不同的病理机制以及细胞凋亡信号转导途径受损部位不同。②Caspase-4的表达特点有助于HL及ALCL的鉴别诊断。

Expression of caspase-4 in Hodgkin''''s lymphoma and anaplastic large cell lymphoma

AIM: This study is based on the result of the study in HL and ALCL employing gene chip technique, in which writer found that there was distinctly different expression of caspase-4 between HL and ALCL cell lines at the level of mRNA. From the point of view, we try to identify at the level of protein whether there is different expression of this gene in HL and ALCL tissues as well. METHODS: HE staining, the monoclonal antibodies CD30 (BerH2), CD15 (C3D-1), CD20 (L26) and CD45RO (UCHL1) were used for selecting the cases of HL and ALCL. Specific high affinitive anti-caspase-4 polyclonal antibody was used by immunohistochemical staining to analyze the expression of caspase-4 in 18 cases of HL and 15 cases of ALCL. RESULTS: The expression of caspase-4 demonstrated a strong positive staining in all ALCL cases (15/15,100%), whereas negative in 16 HL cases (88 8%), while other two cases were weakly stained (11 2%), showing a distinct difference (P<0 01) between two groups. CONCLUSIONS: (1) The diverse expression of caspase-4 gene in HL and ALCL groups implies a different mechanism of oncogenesis and the different defects of signal transduction pathway of apoptosis in these two entities of lymphomas. (2) Clarification of this gene might be useful for the differential diagnosis of HL and ALCL. Furthermore, it probably provides theoretically gene therapy strategies for lymphoma in the future.